Alpha Tau Medical CFO Sells Shares

Raphi Levy, the Chief Financial Officer of Alpha Tau Medical Ltd. (NasdaqCM:DRTS), sold 20,000 shares of the company on June 30, 2026. The shares were sold at an average price of $12 each, amounting to a total transaction value of $240,000. This sale was conducted under a prearranged trading plan.

Insider Buying and Selling at Alpha Tau Medical Ltd.

Raphi Levy has been actively selling shares of Alpha Tau Medical. On June 30, he sold 20,000 shares at $12 each. Earlier, on June 25, he sold another 20,000 shares at $11, following a sale of 17,500 shares at $9.55 on June 23. In addition, Levy sold 32,500 shares on June 3 at $10.84. These sales were part of planned transactions, except for the June 3 sale.

Other Institutional Activity in Alpha Tau Medical

There has been notable institutional activity in Alpha Tau Medical. Hightower Advisors, LLC increased its holdings by 188,440 shares, bringing its total to 874,994 shares worth about $6.19 million. Aquamarine Financial (Cayman) Ltd opened a new position with 721,501 shares valued at approximately $5.10 million. ARK Investment Management LLC also initiated a new stake with 292,134 shares, valued at around $2.07 million. UBS Group AG significantly boosted its position by 265,988 shares to a total of 286,688 shares, worth about $2.03 million. Meanwhile, Northcoast Asset Management LLC reduced its holdings by 10,720 shares, leaving it with 147,138 shares valued at $1.04 million.

Alpha Tau Medical Ltd. Stock Down 15.3%

Shares of Alpha Tau Medical Ltd. traded near $12.40 on Wednesday. The company has a market capitalization of approximately $1.14 billion and a beta of 1.202, indicating moderate volatility. Its 52-week range is between $2.87 and $12.61. The stock's 50-day moving average is $9.39, while the 200-day moving average stands at $6.54. Alpha Tau Medical maintains a strong liquidity position with a current ratio of 7.79 and a quick ratio of 7.31, alongside a debt-to-equity ratio of 20.68.

Analysts Set New Price Targets

Several analysts have set price targets for Alpha Tau Medical. On June 4, 2026, Barclays maintained a 'buy' rating with a target price of $17. Piper Sandler maintained a 'hold' rating with an $8 target on May 19. Earlier, on May 12, Ladenburg Thalmann reaffirmed its 'buy' rating with a $14 target, while HC Wainwright & Co. maintained a 'buy' rating with a $15 target. The consensus target price is $14.20, based on five analyst opinions.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a clinical-stage biotechnology company based in Jerusalem, Israel. It focuses on the research, development, and commercialization of Alpha DaRT, a novel radiation therapy for treating solid tumors. The company's innovative technology is undergoing clinical trials for various cancers, including skin, oral, and pancreatic cancers. Led by CEO Mr. Uzi Sofer, Alpha Tau Medical employs 121 people and aims to advance cancer treatment options.

Bottom Line

Raphi Levy's planned sale of shares in Alpha Tau Medical is a routine insider transaction. Investors keep a close eye on such activity for potential insights into company sentiment. Alpha Tau Medical remains a key player in the biotech sector, with its innovative cancer treatment technology and active institutional interest. As always, remember that insider transactions and institutional holdings are backward-looking and should not be the sole basis for investment decisions.